A new access program and registry developed by the American Society of Clinical Oncology to facilitate use of off-label cancer drugs could serve as a model for independent bodies that could manage early access to experimental therapies, even though ASCO itself is not tackling compassionate use.

ASCO's initiative is designed to match off-label targeted cancer therapies to individual patients likely to benefit based on the genomic profile of their tumors, while collecting data about new uses for approved drugs.